Authors
Latest:
Genetic Susceptibility to Leukemia in PediatricsAs part of our coverage of the ASH Annual Meeting held December 3rd to 6th in San Diego, today we are speaking with Kim Nichols, MD, director of the Cancer Predisposition Division at St. Jude Children's Research Hospital. At this year’s meeting, Dr. Nichols will be participating in a session on genetic susceptibility to leukemia.
Latest:
Nanoparticle-Based Treatment in MelanomaPenn State College of Medicine researchers have discovered a new class of drugs that may keep a deadly form of skin cancer from becoming resistant to treatment.
Latest:
Chlorambucil/Rituximab Combination Delayed Progression in MALT LymphomaPatients with mucosa-associated lymphoid tissue (MALT) lymphoma had improved event-free survival when treated with chlorambucil plus rituximab compared with either therapy alone.
Latest:
Link Between Fanconi Anemia Genetic Mutations and Cancer RiskResearchers have discovered that genetic mutations associated with Fanconi Anemia may also result in a higher risk for certain cancers, even in patients who don't exhibit symptoms of the disease.
Latest:
New Potential Therapy to Prevent ChemobrainAs healthcare providers caring for oncology patients, we are all too familiar with the physical effects of chemotherapy, including chemobrain. A University of Kansas researcher may have identified a possible therapy to prevent this side effect.
Latest:
Understanding the Genomic Landscape of Colorectal TumorsWe spoke with Dr. Luis Diaz about his recent presentation on immunotherapy in colorectal cancer at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.
Latest:
Lenalidomide Maintenance Prolongs PFS in Elderly DLBCLFor the first time, a study shows that using an immunomodulatory agent as maintenance therapy prolongs progression-free survival for patients with diffuse large B-cell lymphoma after first-line treatment with rituximab plus CHOP.
Latest:
Obinutuzumab Plus Chemotherapy Lengthens PFS in Follicular LymphomaObinutuzumab-based therapy is superior to rituximab-based therapy in patients with previously untreated advanced follicular lymphoma.
Latest:
The Multifaceted Experience of Multigene Panel Testing for Breast CancerIn this interview with Mary Daly, MD, PhD, she gives an overview of multigene panel testing for breast cancer, and how they can be used by clinicians to interpret risk and treat accordingly.
Latest:
Study Reveals Treatment Strategy for Triple-Negative Breast CancerMateusz Opyrchal, MD, PhD, talks about how the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.
Latest:
Identifying Circulating Exosomes as a Biomarker in GliomaIn this video, Michael Ciesielski, PhD, of Roswell Park Cancer Institute in Buffalo, talks about circulating exosomes isolated from the serum of malignant glioma patients enrolled in a completed phase I clinical trial of an anti-survivin vaccine (SurVaxM).
Latest:
Study Reveals Mechanism of Antileukemic Effects of Early Childhood VaccinationA new study by an international team led by researchers at the University of California, San Francisco (UCSF), has shed light on the mechanism of action for the anticancer effects of the Haemophilus influenzae Type b (Hib) vaccine, specifically against acute lymphoblastic leukemia (ALL).
Latest:
Metastatic Kidney Cancer: An 'Embarrassment of Riches' For Clear Cell HistologyWhile seven drugs have been approved for clear cell renal cell carcinoma (ccRCC) since 2005, the most appropriate systemic therapy for non-clear cell renal cell carcinoma (nccRCC) is unknown.
Latest:
XRCC2 Gene May Contribute to Testicular Cancer Treatment ResistanceScientists from The Institute of Cancer Research in London identified a gene which may contribute to testicular cancer treatment resistance.
Latest:
Improving Oncology Clinical Trial AccrualWe spoke with Dr. Mikkael Sekeres on the difficulty of cancer patients meeting eligibility criteria for clinical trials.
Latest:
Epidermal Growth Factor Receptor Inhibitor Cutaneous Side EffectsThis slide show highlights some of the cutaneous side effects related to the use of epidermal growth factor receptor inhibitors (EGFRI).
Latest:
A 75-Year-Old Male Develops Painful Erythema Around His Nails After Starting TreatmentA 75-year-old male patient develops painful erythema around his nails 10 weeks after starting cancer treatment. Which medication is most likely responsible?
Latest:
A Multidisciplinary Approach to Treating Immune-Related Adverse EventsWe spoke with Monica Fradkin on ways to help minimize adverse events in patients receiving immunotherapy treatment at the Oncology Nursing Society 42nd Annual Congress, held May 4–7 in Denver.
Latest:
The Personal Side of PalbociclibJust when you think you've run out of treatment options for a patient, new drugs are approved and quickly available. In the past year, there have been dozens of new drugs for all types of solid and blood malignancies. One of the most recent was just approved this year for breast cancer.
Latest:
Studying the Efficacy of Durvalumab and Radiation Therapy in Bladder CancerWe spoke with Dr. Monika Joshi on the use of radiation therapy and durvalumab in patients with locally advanced bladder cancer.
Latest:
Next-Generation Sequencing for SarcomaWe spoke with Mrinal M. Gounder, MD, about next-generation sequencing for sarcoma, and how it can be used to inform treatment decisions and prognosis.
Latest:
Nicholas J. Short, MD, on the Future of ALL and Possibilities for Transplant in These PatientsShort expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.
Latest:
March 2016 News RecapIn case you missed it, check out our March recap featuring some of the latest in clinical trial news, a new indication for Afinitor, how genetics affect prognosis, and more.
Latest:
Novel Nanomedicine Development for GlioblastomaWe spoke with Dr. Priya Kumthekar and Dr. Alexander Stegh about their nucleic acid-based therapeutic development that targets glioblastoma.
Latest:
CDK 4/6 Inhibitors for Breast CancerIn this interview, we are discussing the impact that CDK 4/6 inhibitors are having on specific types of breast cancer.
Latest:
Analyzing Various Molecular Subtypes in Bladder CancerDr. Roland Seiler presented an analysis of how different bladder cancer molecular subtypes respond to neoadjuvant chemotherapy at the 2017 ASCO Genitourinary Cancer Symposium.
Latest:
Is There a Role for Intralesional Therapy in Melanoma?On Monday during ASCO, Dr. Axel Hauschild reviewed the role of intralesional therapy in melanoma in a sub-session of the melanoma abstract review talk entitled “Evolving Utility of Intralesional Therapy for Melanoma.”
Latest:
Patient Ethnicity Differences in Epstein-Barr Virus and DLBCL OutcomesAs part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with Sean Tracy, MD, PhD, at the Mayo Clinic in Rochester, Minnesota.
Latest:
Epidermal Growth Factor Receptor Inhibitor Cutaneous Side EffectsThis slide show highlights some of the cutaneous side effects related to the use of epidermal growth factor receptor inhibitors (EGFRI).
Latest:
Oncology Peer Review On-The-Go: Focus of Current and Emerging Therapies in Follicular LymphomaKirk E. Cahill, MD, and Sonali M. Smith, MD, spoke with CancerNetwork® about their review of the current management and treatment of follicular lymphoma published in the journal ONCOLOGY®.
